Propanc Biopharma's PRP Achieves 85% Tumor Inhibition in Pancreatic Cancer Models

Propanc Biopharma targets the $3 billion+ pancreatic cancer market with its lead proenzyme therapy, PRP. The treatment has demonstrated >85% tumor growth inhibition in preclinical models and has shown promise in reducing fibrosis and resistance markers in the tumor microenvironment. PRP also sensitizes resistant tumors to standard chemo and targets cancer stem cells to cut recurrence risk. Phase 1b First-In-Human trials for PRP are set for 2026.